Format

Send to

Choose Destination
Mol Oncol. 2016 Oct;10(8):1330-43. doi: 10.1016/j.molonc.2016.07.005. Epub 2016 Jul 22.

Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer.

Author information

1
Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
2
Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
3
Department of Gynecology and Obstetrics, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany.
4
Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany.
5
Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: s.riethdorf@uke.de.

Abstract

Modern technologies enable detection and characterization of circulating tumor cells (CTC) in peripheral blood samples. Thus, CTC have attracted interest as markers for therapeutic response in breast cancer. First studies have incorporated CTC analyses to guide therapeutic interventions and stratification of breast cancer patients. Aim of this study was to analyze characteristic features of CTC as biomarker for predicting resistance to HER2-targeted therapies. Therefore, CTC from metastatic breast cancer patients with HER2-negative primary tumors screened for the prospective randomized phase III trial DETECT III were explored for their HER2 status and the presence of PIK3CA mutations. Detection and characterization of HER2 expression of CTC were conducted with the CellSearch(®) system. Fifteen of 179 CTC-positive patients (8.4%) contained ≥1 CTC with strong HER2 expression. Genomic DNA from individual CTC isolated by micromanipulation was propagated by whole genome amplification and analyzed for PIK3CA mutations in exons 9 and 20 by Sanger sequencing. One or more CTC/7.5 mL were detected in 179/290 patients (61.7%). In 109 patients (34.8%), ≥5 CTC/7.5 mL were found. We detected at least one CTC with the mutation p.E542K, p.E545K, p.H1047R, p.H1047L or p.M1043V in 12/33 patients (36.4%). Thirty six of 114 CTC (31.6%) harbored one of these mutations. CTC in individual patients exhibited heterogeneity concerning PIK3CA mutations and HER2 expression. In conclusion, clinically relevant genomic aberrations such as mutations in the hotspot regions of exon 9 and 20 of the PIK3CA gene can be detected in single CTC and might provide insights into mechanisms of resistance to HER2-targeted therapies.

KEYWORDS:

Circulating tumor cells; HER2; Metastatic breast cancer; PIK3CA

PMID:
27491860
PMCID:
PMC5423206
DOI:
10.1016/j.molonc.2016.07.005
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center